Johnson & Johnson Announces $55 Billion Strategic Investment to Accelerate U.S. Pharma and MedTech Leadership

Mar 25, 2025 17:09 CST Updated 17:09

Johnson & Johnson

Medical Device R&D and Manufacturer

Call for Partners: 2025 Global Surgical Robotics Conference

Registration: First Global Ophthalmology Conference | Limited Seats Available

Registration: First Global Cardiovascular Conference | Award Application

Registration: First Global Orthopedics Conference | Award Selection

On March 21, 2025, Johnson & Johnson (NYSE: JNJ) announced that it will invest more than $55 billion (approximately 400 billion RMB) over the next four years into its pharmaceutical and medical device businesses in the United States.

This investment has increased compared to the previous cycle.25%, which will enhance Johnson & Johnson's capabilities in manufacturing, research and development, and technical infrastructure.Johnson & Johnson stated that the investment is expected to deepen its economic influence in the United States.

# Investment Details

In announcingLatest Investment News: Johnson & Johnson has just announced plans to build a new facility in Wilson, North Carolina, worth$2 billion, covering an area of 500,000 square feetTheBiopharmaceutical Production Plant, supporting the production of next-generation therapeutic drugs for cancer, autoimmune diseases, and neurological disorders.

In addition to the newly built plant in North Carolina, Johnson & Johnson also plans toInnovative Pharmaceuticals and Medical Devices BusinessChina ConstructionThreeAdvanced manufacturing plant, and expand several existing sites. Details of the locations have not been disclosed.

Johnson & Johnson also stated that the $550 billion commitment will fundNeuroscience, Robotic Surgery, Oncology, Immunology, and Cardiovascular DiseasesSignificant R&D investment in the field.

At present, the United States is the largest medical technology market globally,95%All of the medical technology R&D takes place in the United States, and the industry supports nearly3 MillionA direct and indirect employment position, with a salary level 37% higher than the national average in China.

# Investment Review

According to Johnson & Johnson's 2024 annual financial report, since January 2024, Johnson & Johnson has completed a number of investments of various sizes:

April 5, 2024Johnson & Johnson announced an agreement to acquire for approximately $13.1 billion (approximately RMB 94.8 billion)Acquisition of Shockwave Medical,The latter is aManufacturer of Intravascular Lithotripsy (IVL) technology.

According to the terms of the agreement, Johnson & Johnson plans to acquire all outstanding shares of Shockwave for $335 per share in cash. The boards of both companies have approved the transaction, which is valued at approximately $13.1 billion.Johnson & Johnson plans to fund this transaction through a combination of cash on hand and debt.

On October 9, 2024, Johnson & Johnson announced the completion of its acquisition of V-Wave, a manufacturer of atrial shunt devices. Under the agreement, Johnson & Johnson will pay V-Wave a sum.$600 million (approximately 4.28 billion yuan)The advance payment.In addition to the upfront payment, Johnson & Johnson is also required to pay potential additional regulatory and commercial milestone payments, bringing the total amount to approximately$1.7 billion (approximately 12.125 billion yuan)。
Related Reading:$1.7 Billion! Johnson & Johnson Completes Major Acquisition
Invested approximately in research and development and other growth opportunities$50 billion, including the announced plan to acquire Intra-Cellular Therapies.
On January 13, 2025, the U.S. biopharmaceutical company Intra-Cellular announced that it had reached an agreement with Johnson & Johnson.Reach a final acquisition agreement.Johnson & Johnson will acquire all outstanding shares of Intra-Cellular for $132.00 per share in cash, with a total equity value of approximately$14.6 billion (approximately 106.87 billion RMB)。
Intra-Cellular is aA company dedicated to developing innovative drugs for central nervous system (CNS) diseases.Over the past 12 months, the share price of Intra-Cellular has shown a significant upward trend, with an increase of approximately40%, its current market value has climbed to approximately$10 billion。
Related Reading:Over 100 Billion! Johnson & Johnson's 2025 Mega Merger!

In January 2024, Johnson & Johnson announced the completion ofAmbrx Biopharma (Anbo Biopharma)The final acquisition agreement, the latter has a proprietary synthetic biotechnology platform for designing and developing next-generation antibody-drug conjugates (ADCs).
Johnson & Johnson to Acquire All Outstanding Shares for $28.00 in Cash per Share, a Premium of Approximately 105% Over the Closing Price, with a Total Equity Value of Approximately$2 billion (approximately 14.3 billion RMB)。
This acquisition presents a unique opportunity for Johnson & Johnson to design, develop, and commercialize targeted oncology therapies, further enriching the company's R&D pipeline in the field of cancer treatment.
On May 16, 2024, Johnson & Johnson$850 Million Acquisition of Proteologix, including a bispecific antibody therapy targeting IL-13 and TSLP, known as PX128. PX128 is about to enter Phase I clinical development for moderate to severe AD and moderate to severe asthma.

On May 28, 2024, Johnson & Johnson announced the signing of a definitive agreement with Numab Therapeutics to acquire its subsidiary, Yellow Jersey Therapeutics, for $1.25 billion in cash, thereby obtaining global rights to NM-26, a bispecific antibody drug for dermatological conditions.

This acquisition further solidifies Johnson & Johnson's market position in the atopic dermatitis treatment field and enriches its R&D pipeline in the immunology sector.

In addition, Johnson & Johnson signed more than 40 smaller collaborations, partnerships, and licensing agreements in 2024, further strengthening its manufacturing capabilities in the United States and globally.

In addition to announcing the investment in North Carolina$2 billionBuilding an advanced technology plant to expand the production of the company's biologics portfolio and pipeline, Johnson & Johnson has also broken ground on the expansion project of its Impella heart pump facilities in Massachusetts and Germany.

# Increase Investment One After Another

This statement from Johnson & Johnson (J&J) followsEli Lilly, Merck & Co., and AmgenFollowing the announcement of investment information from these companies, all of which emphasized their investments in U.S.-based manufacturing,Hopes to reduce the tariff burden through its efforts, while persuading the Trump administration to extend the tax cut policy implemented during his first term and alleviate the impact of the reduction in Medicare prices.

Eli Lilly

2025On February 27, Eli Lilly announcedInvest at least$27 billionBuilding Four New Production Bases in the U.S., This Move Brings Its Recent Total Investment in the U.S. to Over 50 Billion USD. This Investment Aims to Meet the Strong Market Demand for Its Best-Selling Weight Loss Drug Zepbound and Diabetes Drug Mounjaro, and Support the R&D of New Drugs for Other Diseases.

Lilly expects that the new production base will create more than3,000 High-Skilled Positions, including engineers, scientists, operators, and laboratory technicians.

Merck

On March 11, 2025, Merck announced the opening of a brand-new vaccine production facility at its Durham, North Carolina site, with an investment of$1 billion，OccupiesApproximately 225,000 square feet, and it is expected that by 2028, Merck will also increase$8 billionAmerican capital investment.

Amgen

In December 2024, Amgen announced a$1 billionThe expansion plan will establish a second API production facility in North Carolina. Based on the previously announced550 millionDollar investment commitment, a move that will bring the company's total planned investment in Hollis SpringsMore than 1.5 billion US dollars。

On February 24, 2025, Amgen announced that it will open a new technology and innovation facility in Hyderabad, India — Amgen India — focusing on the application of artificial intelligence and data science in the development of novel drugs, or simply put, "AI drug discovery." To accelerate this initiative, Amgen stated that it will invest approximately$200 million。

# Conclusion

Overall, increasing investment in the U.S. allows Johnson & Johnson to better meet the demand for pharmaceuticals and medical devices in the U.S. market. This time,The investment plan will directly create a large number of high-paying, high-tech jobs.Large-scale investment will drive the development of related industrial chains, better optimize production layout, and improve production efficiency and flexibility.